KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quest Diagnostics (DGX) Change in Cash: 2009-2025

Historic Change in Cash for Quest Diagnostics (DGX) over the last 17 years, with Sep 2025 value amounting to $113.0 million.

  • Quest Diagnostics' Change in Cash fell 77.08% to $113.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$332.0 million, marking a year-over-year decrease of 153.46%. This contributed to the annual value of -$137.0 million for FY2024, which is 136.93% down from last year.
  • According to the latest figures from Q3 2025, Quest Diagnostics' Change in Cash is $113.0 million, which was down 13.74% from $131.0 million recorded in Q2 2025.
  • Over the past 5 years, Quest Diagnostics' Change in Cash peaked at $543.0 million during Q4 2023, and registered a low of -$670.0 million during Q2 2021.
  • Moreover, its 3-year median value for Change in Cash was -$49.0 million (2023), whereas its average is $10.6 million.
  • Per our database at Business Quant, Quest Diagnostics' Change in Cash tumbled by 322.22% in 2022 and then spiked by 2,800.00% in 2024.
  • Quest Diagnostics' Change in Cash (Quarterly) stood at -$115.0 million in 2021, then tumbled by 234.78% to -$385.0 million in 2022, then spiked by 241.04% to $543.0 million in 2023, then crashed by 139.59% to -$215.0 million in 2024, then plummeted by 77.08% to $113.0 million in 2025.
  • Its Change in Cash was $113.0 million in Q3 2025, compared to $131.0 million in Q2 2025 and -$361.0 million in Q1 2025.